Beth Snyder Bulik

Beth Snyder Bulik

Stories by Beth Snyder Bulik

FDA

26. Galafold

Galafold is an oral drug versus the IV-infused Fabrazyme, making it more convenient for patients, although not every Fabry patient will be eligible.
blue illustration of neurons

27. Diacomit

The anticonvulsant approved to treat seizures in Dravet syndrome patients older than age two will launch in the U.S. January 2019.
red blood cells

23. Mulpleta

Mulpleta’s approval was the second thrombopoietin receptor agonist in 2018, trailing Dova Pharmaceutical’s nod for Doptelet by two months.